{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:33:52Z","timestamp":1788622432855,"version":"build-2803163510"},"reference-count":40,"publisher":"Pharmaceutical Society of Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,2,14]]},"DOI":"10.1248\/bpb.b25-00689","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T22:08:33Z","timestamp":1771020513000},"page":"316-326","source":"Crossref","is-referenced-by-count":3,"title":["Oxaliplatin-Induced Liver Toxicity: Hepatic Transglutaminase 7 Upregulation Associates with Oxidative Stress, Inflammation, and Apoptosis"],"prefix":"10.1248","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6176-8105","authenticated-orcid":false,"given":"Husah M.","family":"Alowss","sequence":"first","affiliation":[{"name":"Department of Biology, College of Science, Qassim University, Buraydah 52571, Al-Qassim, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7876-560X","authenticated-orcid":false,"given":"Ibtesam S.","family":"Almami","sequence":"additional","affiliation":[{"name":"Department of Biology, College of Science, Qassim University, Buraydah 52571, Al-Qassim, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3729-5135","authenticated-orcid":false,"given":"Heba F.","family":"Gomaa","sequence":"additional","affiliation":[{"name":"Department of Biology, College of Science, Qassim University, Buraydah 52571, Al-Qassim, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Alvarez RG, Karki P, Langleite IE, Bakksj\u00f8 R, Eichacker LA, Furnes C. Characterisation of a novel cold-adapted calcium-activated transglutaminase: implications for medicine and food processing. <i>FEBS Open Bio<\/i>, <b>10<\/b>, 495\u2013506 (2020).","DOI":"10.1002\/2211-5463.12826"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Chermnykh ES, Alpeeva EV, Vorotelyak EA. Transglutaminase 3: the involvement in epithelial differentiation and cancer. <i>Cells<\/i>, <b>9<\/b>, 1996 (2020).","DOI":"10.3390\/cells9091996"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Min B, Chung KC. New insight into transglutaminase 2 and link to neurodegenerative diseases. <i>BMB Rep.<\/i>, <b>51<\/b>, 5\u201313 (2018).","DOI":"10.5483\/BMBRep.2018.51.1.227"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Odii BO, Coussons P. Biological functionalities of transglutaminase 2 and the possibility of its compensation by other members of the transglutaminase family. <i>ScientificWorldJournal<\/i>, <b>2014<\/b>, 714561 (2014).","DOI":"10.1155\/2014\/714561"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Fukui M, Kuramoto K, Yamasaki R, Shimizu Y, Itoh M, Kawamoto T, Hitomi K. Identification of a highly reactive substrate peptide for transglutaminase 6 and its use in detecting transglutaminase activity in the skin epidermis. <i>FEBS J.<\/i>, <b>280<\/b>, 1420\u20131429 (2013).","DOI":"10.1111\/febs.12133"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Tatsukawa H, Hitomi K. Role of transglutaminase 2 in cell death, survival, and fibrosis. <i>Cells<\/i>, <b>10<\/b>, 1842 (2021).","DOI":"10.3390\/cells10071842"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Szondy Z, Korponay-Szab\u00f3 I, Kir\u00e1ly R, Sarang Z, Tsay GJ. Transglutaminase 2 in human diseases. <i>Biomedicine<\/i>, <b>7<\/b>, 15 (2017).","DOI":"10.1051\/bmdcn\/2017070315"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Elli L, Bergamini CM, Bardella MT, Schuppan D. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver. <i>Dig. Liver Dis.<\/i>, <b>41<\/b>, 541\u2013550 (2009).","DOI":"10.1016\/j.dld.2008.12.095"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Meshram DD, Pike CVS, Coussons PJ. Inhibition of Transglutaminase 2 activity increases cisplatin cytotoxicity in a model of human hepatocarcinoma chemotherapy. <i>Eur. J. Pharmacol.<\/i>, <b>815<\/b>, 332\u2013342 (2017).","DOI":"10.1016\/j.ejphar.2017.09.035"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Almami IS, Aldubayan MA, Felemban SG, Alyamani N, Howden R, Robinson AJ, Pearson TDZ, Boocock D, Algarni AS, Garner AC, Griffin M, Bonner PLR, Hargreaves AJ. Neurite outgrowth inhibitory levels of organophosphates induce tissue transglutaminase activity in differentiating N2a cells: evidence for covalent adduct formation. <i>Arch. Toxicol.<\/i>, <b>94<\/b>, 3861\u20133875 (2020).","DOI":"10.1007\/s00204-020-02852-w"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Cao L, Petrusca DN, Satpathy M, Nakshatri H, Petrache I, Matei D. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. <i>Carcinogenesis<\/i>, <b>29<\/b>, 1893\u20131900 (2008).","DOI":"10.1093\/carcin\/bgn158"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Klobu\u010dar M, Grb\u010di\u0107 P, Paveli\u0107 SK, Jonji\u0107 N, Visentin S, Sedi\u0107 M. Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and \u03b21 integrin\/FAK-mediated signalling. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>503<\/b>, 843\u2013848 (2018).","DOI":"10.1016\/j.bbrc.2018.06.085"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Yu W, Zheng Z, Wei W, Li L, Zhang Y, Sun Y, Cao J, Zang W, Shao J. Raf1 interacts with OIP5 to participate in oxaliplatin-induced neuropathic pain. <i>Life Sci.<\/i>, <b>281<\/b>, 119804 (2021).","DOI":"10.1016\/j.lfs.2021.119804"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Chen W, Lian W, Yuan Y, Li M. The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress. <i>Cell Death Dis.<\/i>, <b>10<\/b>, 600 (2019).","DOI":"10.1038\/s41419-019-1824-6"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Tabassum H, Waseem M, Parvez S, Qureshi MI. Oxaliplatin-induced Oxidative stress provokes toxicity in isolated rat liver mitochondria. <i>Arch. Med. Res.<\/i>, <b>46<\/b>, 597\u2013603 (2015).","DOI":"10.1016\/j.arcmed.2015.10.002"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Azevedo MI, Pereira AF, Nogueira RB, Rolim FE, Brito GA, Wong DV, Lima-J\u00fanior RC, de Albuquerque Ribeiro R, Vale ML. The antioxidant effects of the flavonoids rutin and quercetin inhibit oxaliplatin-induced chronic painful peripheral neuropathy. <i>Mol. Pain<\/i>, <b>9<\/b>, 1744-8069-9-53 (2013).","DOI":"10.1186\/1744-8069-9-53"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Rogers BB, Cuddahy T, Briscella C, Ross N, Olszanski AJ, Denlinger CS. Oxaliplatin: detection and management of hypersensitivity reactions. <i>Clin. J. Oncol. Nurs.<\/i>, <b>23<\/b>, 68\u201375 (2019).","DOI":"10.1188\/19.CJON.68-75"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Kalemci S, Tanr\u0131verdi O, \u015eim\u015fek A, Aksun S, Celik O, Barutca S, Zeybek A, Demirci B. Evaluation of oxaliplatin-induced pulmonary toxicity in rats. <i>Contemp. Oncol.<\/i>, <b>23<\/b>, 151\u2013156 (2019).","DOI":"10.5114\/wo.2019.89242"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Lu Y, Lin Y, Huang X, Wu S, Wei J, Yang C. Oxaliplatin aggravates hepatic oxidative stress, inflammation and fibrosis in a non-alcoholic fatty liver disease mouse model. <i>Int. J. Mol. Med.<\/i>, <b>43<\/b>, 2398\u20132408 (2019).","DOI":"10.3892\/ijmm.2019.4154"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kim S-G, Jeong JH, Park YW, Song JY, Kim AS, Choi JY, Chae WS. 4-Hexylresorcinol inhibits transglutaminase-2 activity and has synergistic effects along with cisplatin in KB cells. <i>Oncol. Rep.<\/i>, <b>25<\/b>, 1597\u20131602 (2011).","DOI":"10.3892\/or.2011.1218"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Ientile R, Caccamo D, Griffin M. Tissue transglutaminase and the stress response. <i>Amino Acids<\/i>, <b>33<\/b>, 385\u2013394 (2007).","DOI":"10.1007\/s00726-007-0517-0"},{"key":"22","unstructured":"22) Guide for the Care and Use of Laboratory Animals. National Academies Press: Washington, D.C., 2011."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Ashry M, Galal ELSahra D, Abdel-Wahhab KG, Abdelsalam ME, Mourad HH, El-Bitar AMH, Gomaa HF. <i>Saussurea costus<\/i> extract has anti-inflammatory, antioxidant, and hormonal effects against testicular toxicity induced by oxaliplatin in male albino rats. <i>Iranian Journal of Toxicology<\/i>, <b>16<\/b>, 83\u201390 (2022).","DOI":"10.32598\/IJT.16.2.894.1"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Fu S, Wu D, Jiang W, Li J, Long J, Jia C, Zhou T. Molecular biomarkers in drug-induced liver injury: challenges and future perspectives. <i>Front. Pharmacol.<\/i>, <b>10<\/b>, 1667 (2020).","DOI":"10.3389\/fphar.2019.01667"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Guo L, Ding J, Zhou W. Harnessing bacteria for tumor therapy: Current advances and challenges. <i>Chin. Chem. Lett.<\/i>, <b>35<\/b>, 108557 (2024).","DOI":"10.1016\/j.cclet.2023.108557"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Soltani F, Kaartinen MT. Transglutaminases in fibrosis\u2014overview and recent advances. <i>Am. J. Physiol. Cell Physiol.<\/i>, <b>325<\/b>, C885\u2013C894 (2023).","DOI":"10.1152\/ajpcell.00322.2023"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Guo K, van den Beucken T. Advances in drug-induced liver injury research: <i>in vitro<\/i> models, mechanisms, omics and gene modulation techniques. <i>Cell Biosci.<\/i>, <b>14<\/b>, 134 (2024).","DOI":"10.1186\/s13578-024-01317-2"},{"key":"28","unstructured":"28) Aldubayan MA, Almami IS, Felemban SG, Alhowail AH, Bonner PLR, Hargreaves AJ. Organophosphates modulate tissue transglutaminase activity in differentiated C6 neural cells. <i>Eur. Rev. Med. Pharmacol. Sci.<\/i>, <b>26<\/b>, 168\u2013182 (2022)."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Lloyd SM, He Y. Exploring extracellular matrix crosslinking as a therapeutic approach to fibrosis. <i>Cells<\/i>, <b>13<\/b>, 438 (2024).","DOI":"10.3390\/cells13050438"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Lyu C, Kong W, Zhang Y, Liu Z, Liang K, Du Y. Transglutaminase-crosslinked extracellular matrix in cirrhotic liver tissues provides pro-fibrotic mechano-microenvironment for cells. <i>Life Med.<\/i>, <b>2<\/b>, lnad030 (2023).","DOI":"10.1093\/lifemedi\/lnad030"},{"key":"31","unstructured":"31) Alharbi NS, Almami IS. Activation and upregulation of keratinocyte and epidermal transglutaminases are associated with depletion of their substrates in psoriatic lesions. <i>Eur. Rev. Med. Pharmacol. Sci.<\/i>, <b>27<\/b>, 11281\u201311293 (2023)."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Allison R, Guraka A, Shawa IT, Tripathi G, Moritz W, Kermanizadeh A. Drug induced liver injury\u2014a 2023 update. <i>J. Toxicol. Environ. Health B Crit. Rev.<\/i>, <b>26<\/b>, 442\u2013467 (2023).","DOI":"10.1080\/10937404.2023.2261848"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Almami I, Dickenson JM, Hargreaves AJ, Bonner PLR. Modulation of transglutaminase 2 activity in H9c2 cells by PKC and PKA signalling: a role for transglutaminase 2 in cytoprotection. <i>Br. J. Pharmacol.<\/i>, <b>171<\/b>, 3946\u20133960 (2014).","DOI":"10.1111\/bph.12756"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Tarvainen I, Nunn RC, Tuominen RK, J\u00e4ntti MH, Talman V. Protein kinase A-mediated effects of protein kinase C partial agonist 5-(hydroxymethyl)isophthalate 1a3 in colorectal cancer cells. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>380<\/b>, 54\u201362 (2022).","DOI":"10.1124\/jpet.121.000848"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Eckert RL, Kaartinen MT, Nurminskaya M, Belkin AM, Colak G, Johnson GV, Mehta K. Transglutaminase regulation of cell function. <i>Physiol. Rev.<\/i>, <b>94<\/b>, 383\u2013417 (2014).","DOI":"10.1152\/physrev.00019.2013"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Kari S, Subramanian K, Altomonte IA, Murugesan A, Yli-Harja O, Kandhavelu M. Programmed cell death detection methods: a systematic review and a categorical comparison. <i>Apoptosis<\/i>, <b>27<\/b>, 482\u2013508 (2022).","DOI":"10.1007\/s10495-022-01735-y"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Nagata S. Apoptotic DNA Fragmentation. <i>Exp. Cell Res.<\/i>, <b>256<\/b>, 12\u201318 (2000).","DOI":"10.1006\/excr.2000.4834"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Kunoki S, Tatsukawa H, Sakai Y, Kinashi H, Kariya T, Suzuki Y, Mizuno M, Yamaguchi M, Sasakura H, Ikeno M, Takeuchi K, Ishimoto T, Hitomi K, Ito Y. Inhibition of transglutaminase 2 reduces peritoneal injury in a chlorhexidine-induced peritoneal fibrosis model. <i>Lab. Invest.<\/i>, <b>103<\/b>, 100050 (2023).","DOI":"10.1016\/j.labinv.2022.100050"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Maimaitijiang A, Huang Q, Wu Y, Sun S, Chen Q. Transglutaminase 2 inhibition ameliorates cardiac fibrosis in myocardial infarction by inducing M2 macrophage polarization <i>in vitro<\/i> and <i>in vivo<\/i>. <i>Cytojournal<\/i>, <b>21<\/b>, 58 (2024).","DOI":"10.25259\/Cytojournal_32_2024"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Lin Y, Li Y, Hu X, Liu Z, Chen J, Lu Y, Liu J, Liao S, Zhang Y, Liang R, Lin Y, Li Q, Liang C, Yuan C, Liao X. The hepatoprotective role of reduced glutathione and its underlying mechanism in oxaliplatin-induced acute liver injury. <i>Oncol. Lett.<\/i>, <b>15<\/b>, 2266\u20132272 <b>(<\/b>2017).","DOI":"10.3892\/ol.2017.7594"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/2\/49_b25-00689\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:26:15Z","timestamp":1771039575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/2\/49_b25-00689\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00689","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"article-number":"b25-00689"}}